Department of Population Health Sciences Division of Health System Innovation and Research University of Utah School of Medicine Salt Lake City UT.
Department of Medicine Renal-Electrolyte and Hypertension Division Perelman School of Medicine at the University of Pennsylvania Philadelphia PA.
J Am Heart Assoc. 2021 Jun;10(11):e020997. doi: 10.1161/JAHA.121.020997. Epub 2021 May 19.
The COVID-19 pandemic is a public health crisis, having killed more than 514 000 US adults as of March 2, 2021. COVID-19 mitigation strategies have unintended consequences on managing chronic conditions such as hypertension, a leading cause of cardiovascular disease and health disparities in the United States. During the first wave of the pandemic in the United States, the combination of observed racial/ethnic inequities in COVID-19 deaths and social unrest reinvigorated a national conversation about systemic racism in health care and society. The 4th Annual University of Utah Translational Hypertension Symposium gathered frontline clinicians, researchers, and leaders from diverse backgrounds to discuss the intersection of these 2 critical social and public health phenomena and to highlight preexisting disparities in hypertension treatment and control exacerbated by COVID-19. The discussion underscored environmental and socioeconomic factors that are deeply embedded in US health care and research that impact inequities in hypertension. Structural racism plays a central role at both the health system and individual levels. At the same time, virtual healthcare platforms are being accelerated into widespread use by COVID-19, which may widen the divide in healthcare access across levels of wealth, geography, and education. Blood pressure control rates are declining, especially among communities of color and those without health insurance or access to health care. Hypertension awareness, therapeutic lifestyle changes, and evidence-based pharmacotherapy are essential. There is a need to improve the implementation of community-based interventions and blood pressure self-monitoring, which can help build patient trust and increase healthcare engagement.
截至 2021 年 3 月 2 日,COVID-19 大流行已导致超过 514,000 名美国成年人死亡,这是一场公共卫生危机。COVID-19 缓解策略对管理高血压等慢性病产生了意外后果,高血压是美国心血管疾病和健康差异的主要原因。在美国 COVID-19 大流行的第一波期间,观察到 COVID-19 死亡中的种族/族裔不平等现象以及社会动荡,重新引发了一场关于医疗保健和社会中系统性种族主义的全国性对话。犹他大学第 4 届转化高血压研讨会汇集了来自不同背景的一线临床医生、研究人员和领导者,讨论了这两个关键的社会和公共卫生现象的交集,并强调了 COVID-19 加剧的高血压治疗和控制方面已经存在的差异。讨论强调了深深植根于美国医疗保健和研究中的环境和社会经济因素,这些因素对高血压的不平等产生了影响。结构性种族主义在卫生系统和个人层面都起着核心作用。与此同时,由于 COVID-19,虚拟医疗保健平台正在加速广泛使用,这可能会扩大财富、地理位置和教育水平等方面的医疗保健获取差距。血压控制率正在下降,尤其是在有色人种社区以及没有医疗保险或无法获得医疗保健的人群中。提高高血压意识、生活方式治疗改变和基于证据的药物治疗至关重要。需要改进基于社区的干预措施和血压自我监测的实施,这有助于建立患者信任并增加医疗保健参与度。